Search results

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 04 November 2020

Anamnestic reactions (renewed rapid production of antibody on 2nd or subsequent encounter with same antigen) with rise in human factor VIII and/or porcine factor VIII inhibitors have been very...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 10 November 2020

Kaposi’s sarcoma has been added as a potential adverse effect of treatment (frequency unknown)

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 10 November 2020

Hallucinations have been added as a potential adverse effect of treatment (frequency unknown).

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 09 November 2020

This product is licensed for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media; otitis in...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 09 November 2020

Ozanimod hydrochloride, a selective immunosuppressant (sphingosine 1-phosphate receptor modulator), is licensed for the treatment of adult patients with relapsing remitting multiple sclerosis with...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 28 October 2020

An increase in blood phosphorus has been added to SPC as an adverse effect of unknown frequency.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 27 October 2020

SPC revised to advise breastfeeding is not expected to result in exposure of the infant to linaclotide and thus it can be used during breast-feeding.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 27 October 2020

SPCs revised to include drug reaction with eosinophilia and systemic symptoms (DRESS), as an adverse effect of treatment of unknown frequency.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 20 October 2020

Sleep apnoea syndrome has been added as a potential adverse effect of treatment (frequency unknown). The SPC also notes that opioids may also cause worsening of pre-existing sleep apnoea.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

electronic Medicines Compendium - eMC (Remove filter)

Published by electronic Medicines compendium, 20 October 2020

SPC now states that co-administration with hydroxyzine is contra-indicated owing to a potential additive risk of QT interval prolongation.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)